RePOWER
Prospective, Observational Study

A prospective, observational study of patients with genetically confirmed or suspected primary mitochondrial myopathy (PMM). Patients will be asked to complete questionnaires about their current symptoms and quality of life, and perform functional assessments such as 6-Minute Walk Test (6MWT), Triple-Timed Up-and-Go Test (3TUG) and 5-Times Sit-to-Stand Test (5XSST).

0
FDA-APPROVED TREATMENTS

This trial will assess approximately 300 patients*

AGES 16-65

Enrolled patients will complete the single enrollment (baseline) visit

TRIAL BEGAN
Q1 2017

* The trial investigator identified potential patients for this study from existing medical records of patients with PMM at the site.

TRIAL SITES



~North America
~Europe
~Australia

ENDPOINTS

PRIMARY

To assess the relationship of genetic test results (genotype) to the clinical presentation (phenotype) of patients with PMM

To compare local and regional differences in standard of care and management of patients with PMM

SECONDARY

To identify potential patients for an upcoming Phase 3, randomized, double-blind, placebo-controlled, clinical study examining elamipretide for the treatment of PMM

To compare local and regional differences in genetic testing methodologies for PMM

For more information, please visit ClinicalTrials.gov.

Stealth BIOTHERAPEUTICS